307 patents currently held
44 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
58
Ending by 2030
Jan 2027
Next term end
188
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2034 · High confidence
Also notable
Ends Mar 2034 · Medium confidence
Also notable
Ends Nov 2030 · High confidence
Also notable
Ends Oct 2027 · High confidence
Also notable
Ends Jun 2034 · High confidence
Also notable
Ends Jan 2036 · High confidence
Also notable
Ends Apr 2030 · Medium confidence
Also notable
Ends Aug 2038 · High confidence
Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances
US 9,650,412
Cited by 68 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
FC Containing Polypeptides with Altered Glycosylation and Reduced Effector Function
US 9,790,268
Cited by 40 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Amorphous and a Crystalline Form of Genz 112638 Hemitartrate as Inhibitor of Glucosylceramide Synthase
US 11,458,119
Cited by 11 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2030.
Stepped Cannula
US 7,815,623
The most cited patent in this portfolio, cited by 129 later US patents, top 5% of utility patents granted in 2010 in our data. Protection runs to 2027.
Inhibitors of T-Cell Activation
US 9,834,604
Cited by 57 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Analytical Ultracentrifugation for Characterization of Recombinant Viral Particles
US 11,639,887
Cited by 6 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2036.
Gene Therapy for Neurodegenerative Disorders
US 10,369,193
Cited by 20 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2030.
Methods for Detecting Aav
US 11,698,377
Cited by 6 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2038.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 4 fees due Dec 11 to 30, 2026 · next Dec 11
- 3 fees due Jan 9 to 11, 2027 · next Jan 9
- 5 fees due Feb 4 to 25, 2027 · next Feb 4
- 3 fees due Mar 8 to 22, 2027 · next Mar 8
- 6 fees due Apr 1 to 30, 2027 · next Apr 1
- 5 fees due May 3 to 14, 2027 · next May 3
- 8 fees due Jun 3 to 26, 2027 · next Jun 3
- 4 fees due Jul 2 to 30, 2027 · next Jul 2
- 8 fees due Aug 13 to 27, 2027 · next Aug 13
- 3 fees due Sep 5 to 30, 2027 · next Sep 5
- 3 fees due Oct 2 to 28, 2027 · next Oct 2
- 4 fees due Nov 3 to 12, 2027 · next Nov 3
Recent changes
- Nov 13Assignment recorded on 1 record: Ayloo, Swathi and 1 other to Genzyme Corporation Recorded Nov 13, 2026, executed Aug 24, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76744, frame 331.
- Oct 8Assignment recorded on 1 record: Visirna Therapeutics HK Limited to Genzyme Corporation Recorded Oct 8, 2026, executed Feb 28, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76312, frame 672.
- 9 of the patents on this record were granted since Aug 21, 2026
- 5 terms have ended since Aug 21, 2026
What they patent
The largest of its 188 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,455,248 | Powder Delivery Device In force · High confidence | In force | High confidence | |
| US 8,926,967 | Intraventricular Enzyme Delivery for Lysosomal Storage Diseases In force · High confidence | In force | High confidence | |
| US 10,080,783 | Intraventricular Enzyme Delivery for Lysosomal Storage Diseases In force · High confidence | In force | High confidence | |
| US 11,253,485 | Slow Intraventricular Delivery In force · High confidence | In force | High confidence | |
| US 8,062,282 | Methods and Apparatus for Temporarily Occluding Body Openings In force · High confidence | In force | High confidence | |
| US 9,890,394 | Gene Therapy for Amyotrophic Lateral Sclerosis and Other Spinal Cord Disorders In force · High confidence | In force | High confidence | |
| US 10,920,245 | Gene Therapy for Amyotrophic Lateral Sclerosis and Other Spinal Cord Disorders In force · High confidence | In force | High confidence | |
| US 7,815,623 | Stepped Cannula In force · High confidence | In force | High confidence | |
| US 11,554,161 | Gene Therapy for Amyotrophic Lateral Sclerosis and Other Spinal Cord Disorders In force · High confidence | In force | High confidence | |
| US 8,163,926 | Process for the Synthesis of Piperidinyl Sulphonate Esters In force · High confidence | In force | High confidence |
Also on record, not counted in the 307: 44 patents in force now held by others · 292 patents ended · 161 applications pending · 408 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.